

CORRECTION

Open Access



# Correction: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45 $\alpha$ pathway

Gangjun Yuan<sup>1,2†</sup>, Xin Chen<sup>1,2†</sup>, Zhuowei Liu<sup>2†</sup>, Wensu Wei<sup>1,2</sup>, Qinghai Shu<sup>3</sup>, Hussein Abou-Hamdan<sup>4</sup>, Lijuan Jiang<sup>1</sup>, Xiangdong Li<sup>1</sup>, Rixin Chen<sup>2</sup>, Laurent Désaubry<sup>4,5\*</sup>, Fangjian Zhou<sup>1,2\*</sup> and Dan Xie<sup>1\*</sup>

**Correction: J Exp Clin Cancer Res 37, 21 (2018)**  
<https://doi.org/10.1186/s13046-018-0695-5>

Following publication of the original article [1], an error was identified in the image of PHB Control and Paclitaxel (10 mg/kg) in Fig. 5d.

The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.

#### Author details

<sup>1</sup>State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. <sup>2</sup>Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. <sup>3</sup>School of Material Science and Engineering, Beijing Institute of Technology, Beijing, China. <sup>4</sup>Therapeutic Innovation

The original article can be found online at <https://doi.org/10.1186/s13046-018-0695-5>.

<sup>†</sup>Gangjun Yuan, Xin Chen and Zhuowei Liu contributed equally to this work.

\*Correspondence: [desaubry@unistra.fr](mailto:desaubry@unistra.fr); [zhoufj@sysucc.org.cn](mailto:zhoufj@sysucc.org.cn); [xiedan@sysucc.org.cn](mailto:xiedan@sysucc.org.cn)

<sup>1</sup> State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

<sup>2</sup> Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China

<sup>5</sup> Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China

Full list of author information is available at the end of the article

Laboratory, UMR7200, CNRS/University of Strasbourg, Strasbourg, France.

<sup>5</sup>Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.


Published online: 30 September 2022

#### Reference

1. Yuan G, Chen X, Liu Z, et al. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45 $\alpha$  pathway. *J Exp Clin Cancer Res*. 2018;37:21. <https://doi.org/10.1186/s13046-018-0695-5>.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 5** FL3 inhibits growth of UCB tumor xenografts in vivo. **a** The xenograft tumors were isolated from mice at the end of study. **b** Tumor volumes were recorded from the date of injection to the end of the study (mean,  $n = 7$ ). **c** Histograms present the mean tumor weight in each group, means  $\pm$  SD ( $n = 7$ ). \*\* $P < 0.01$ , \*\*\* $P < 0.001$  indicates a significant difference between FL3-treated mice and control mice. **d** Tumors were embedded in paraffin and 5  $\mu$ m thick sections were used for immunohistochemistry analysis with PHB or GADD45a antibody. **e** Body weights of mice were recorded along with the records of tumor volumes as dashed lines (mean,  $n = 7$ ). **f** Main organs including heart, kidney, liver, and lung were removed from mice and embedded in paraffin for further hematoxylin eosin staining